Comparative Effectiveness of Early Natalizumab Treatment in JC Virus-Negative Relapsing-Remitting Multiple Sclerosis
We estimated the long-term risks and benefits of disease modifying therapies. Benefits were favored by natalizumab with minimal increased risks in the negative anti-JC virus population.